A brief review on Pleiotropic effects of Pirfenidone - novel and ongoing outcomes

Simple item page
dc.contributor.authorC, Ravishankaren_US
dc.contributor.authorRoy, Jaydeepen_US
dc.contributor.authorAmmunje, Damodar Nayaken_US
dc.contributor.authorJ, Anbuen_US
dc.contributor.authorMohammad, Azamthullaen_US
dc.date.accessioned2020-09-24T07:34:31Z
dc.date.available2020-09-24T07:34:31Z
dc.date.issued2019-02
dc.description.abstractPresently, there is a huge hype and excitement in the field of synthetic biologics and engineering regarding growing cases of their implication in various fields including health care systems. Furthermore, despite its large body of suggestive and fascinating accomplishments, the synthetic area is always been subject of much more prejudice and debate. However, over a couple of years, the generation of researchers had tested one of such disease modifying compound Pirfenidone (EsbrietĀ®), to unleash their potential in the different disciplines of interventional pharmacology and therapy. In this pipeline, depending on its success of multiple missions, in context to advancing the therapy for different diseases, it became the first prescribed medicine to treat the people with one characteristic lung disorder called idiopathic pulmonary fibrosis (IPF). This review discusses the different therapeutic strategies beyond its well-known anti-fibrotic activity in several well-characterized animals, cell-based and human models and also regarding facts of Pirfenidone (PFD) as anti-inflammatory, anti-fibrinogenic, anti-oxidants including in the treatment of diabetic neuropathy, liver cirrhosis etc. This review also contains current investigations, focusing mainly on the novel findings and their outcomes in improving the quality of life of patients with different conditions and also suggests their implication on the basis of fundamental existential evidences to break the major impediment in transforming this disease-modifying drug into a personalized medicine.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, 560054, India*en_US
dc.identifier.citationC Ravishankar, Roy Jaydeep, Ammunje Damodar Nayak, J Anbu, Mohammad Azamthulla. A brief review on Pleiotropic effects of Pirfenidone - novel and ongoing outcomes. International Journal of Research and Development in Pharmacy & Life Sciences (IJRDPL). 2019 Feb; 8(1): 6-14en_US
dc.identifier.issn2279-0238
dc.identifier.issn2393-932X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/203828
dc.languageenen_US
dc.publisherSociety for research and Development in Educationen_US
dc.relation.issuenumber1en_US
dc.relation.volume8en_US
dc.source.urihttps://doi.org/10.21276/IJRDPL.2278-0238.2019.8(1).6-14en_US
dc.subjectPirfenidone (PFD)en_US
dc.subjectAnti-fibroticen_US
dc.subjectAnti-Inflammatoryen_US
dc.subjectAnti-oxidanten_US
dc.subjectIdiopathic pulmonary fibrosis (IPF)en_US
dc.titleA brief review on Pleiotropic effects of Pirfenidone - novel and ongoing outcomesen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrdpl2019v8n1p6.pdf
Size:
618.29 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Research and Development in Pharmacy and Life Sciences